Data from the ORAL Surveillance study (NCT02092467) suggested that malignancy risk is higher in people with active RA aged ≥50 years when using the JAK 1 inhibitor filgotinib vs TNF inhibitors. In this touchIMMUNOLOGY interview we spoke with Prof. Xavier Mariette (Paris-Saclay University, Ile-de-France, France) around his study investigating the malignancy incidence and event rates in clinical trials of filgotinib for the treatment of rheumatoid arthritis and ulcerative colitis.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs.’ (Abstract number: 0277) was presented at the ACR Convergence, November 10–14, 2022.
- What is known about the malignancy risk of janus kinase (JAK) 1 inhibitors in the treatment of rheumatoid arthritis (RA) and ulcerative colitis (UC)? (0:11)
- What were the aims and design of your study? (0:48)
- What was the incidence of malignancy events and what risk factors were identified? (2:19)
- What was the impact of filgotinib on malignancies in UC and RA? (3:34)
- What are the key take home messages of this study? (4:33)
Disclosures: Xavier Mariette discloses receiving honoraria from Astra-Zeneca, BMS, Galapagos, GSK, Novartis, and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatic Diseases
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Catherine Sims, ACR 2022: Azathioprine metabolite levels throughout pregnancy in women with rheumatic disease
Women with rheumatic disease, such as systemic lupus erythematosus, are often prescribed azathioprine to control disease activity during pregnancy. However, the changes in azathioprine metabolite levels throughout pregnancy in such women are yet to be well-characterized. It was a pleasure to talk with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study investigating […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!